Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20169212 | 1.00 | CHRM3 (0.83) | CHRM3ADRB2 | |
| SCHEMBL19292639 | 0.95 | CHRM3 (0.82) | CHRM3ADRB2 | |
| SCHEMBL18713883 | 0.95 | CHRM3 (0.82) | CHRM3ADRB2 | |
| SCHEMBL19292633 | 0.94 | CHRM3 (0.83) | CHRM3ADRB2 | |
| SCHEMBL20169211 | 0.93 | ADRB2 (0.83) | CHRM3ADRB2 | |
| SCHEMBL20169207 | 0.92 | ADRB2 (0.84) | CHRM3ADRB2 | |
| SCHEMBL18714053 | 0.92 | CHRM3 (0.83) | CHRM3ADRB2 | |
| SCHEMBL18713809 | 0.92 | CHRM3 (0.83) | CHRM3ADRB2 | |
| SCHEMBL19730087 | 0.91 | CHRM3 (0.83) | CHRM3ADRB2 | |
| SCHEMBL738894 | 0.91 | CHRM3 (1.00) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-9975875-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2018-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | CHRM3 16/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.